BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19810774)

  • 1. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
    Wolf D; Rumpold H
    Drug Saf; 2009; 32(11):1001-15. PubMed ID: 19810774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E; Judson I
    Arch Toxicol; 2012 Jan; 86(1):1-12. PubMed ID: 21717109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
    Hernández-Boluda JC; Cervantes F
    Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
    Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
    Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
    Nadal E; Olavarria E
    Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
    Widmer N; Decosterd LA; Leyvraz S; Duchosal MA; Rosselet A; Debiec-Rychter M; Csajka C; Biollaz J; Buclin T
    Br J Cancer; 2008 May; 98(10):1633-40. PubMed ID: 18475296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib.
    Lyseng-Williamson K; Jarvis B
    Drugs; 2001; 61(12):1765-74; discussion 1775-6. PubMed ID: 11693465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
    Heartin E; Walkinshaw S; Clark RE
    Leuk Lymphoma; 2004 Jun; 45(6):1307-8. PubMed ID: 15360020
    [No Abstract]   [Full Text] [Related]  

  • 19. [STI571: a summary of targeted therapy].
    Czyz M; Jakubowska J
    Postepy Hig Med Dosw (Online); 2006; 60():677-96. PubMed ID: 17245318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.